Enveric Biosciences, Inc.
ENVB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $40 | $40 | $81 | $82 |
| Gross Profit | -$40 | -$40 | -$81 | -$82 |
| % Margin | – | – | – | – |
| R&D Expenses | $402 | $1,260 | $746 | $1,105 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,431 | $1,219 | $1,360 | $1,986 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,834 | $2,479 | $2,107 | $3,091 |
| Operating Income | -$1,874 | -$2,519 | -$2,188 | -$3,174 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$0 | $3 | $26 |
| Pre-Tax Income | -$1,874 | -$2,519 | -$2,185 | -$3,147 |
| Tax Expense | $0 | $0 | $0 | $7 |
| Net Income | -$1,874 | -$2,519 | -$2,185 | -$3,155 |
| % Margin | – | – | – | – |
| EPS | -10.81 | -11.64 | -14,584.44 | -69.84 |
| % Growth | 7.1% | 99.9% | -20,782.6% | – |
| EPS Diluted | -10.81 | -11.64 | -14,584.44 | -57.84 |
| Weighted Avg Shares Out | 313 | 216 | 0 | 42 |
| Weighted Avg Shares Out Dil | 313 | 216 | 0 | 55 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $40 | $40 | $81 | $82 |
| EBITDA | -$1,833 | -$2,479 | -$2,104 | -$3,065 |
| % Margin | – | – | – | – |